At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 115 enrolled
Drug / intervention
Glucose +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial
In Brief
A Phase 4 clinical trial evaluating Glucose and Polidocanol with Glucose for Varicose Veins and Telangiectasis. Completed, enrolled 115 participants across 1 site.
Detailed Summary
It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaricose Veins, Telangiectasis
CountriesBrazil
CollaboratorsFundação de Amparo à Pesquisa do Estado de São Paulo
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJan 2015
First PostedJan 2016
Primary CompletionSep 2016
Study CompletionNov 2016
TodayJul 2026
First PostedJan 15, 2016
Enrollment StartJan 1, 2015
Primary CompletionSep 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.5 years ago
Interventions
Glucosedrug
Sclerotherapy of telangiectasis in one lower limb.
Polidocanol with Glucosedrug
Sclerotherapy of telangiectasis in one lower limb.